// App-Quantinova.ai

553 : Ibrutinib, a BTK inhibitor, impairs the generation and function of myeloid derived suppressor cells

Researchers

Presenter

  • Andrew R. Stiff

Principal Investigators

  • Prashant Trikha

  • Robert Wesolowski

  • Kari Kendra

  • Sarvani Uppati

  • David Abood

  • Elizabeth McMichael

  • Megan Duggan

  • Amanda Campbell

  • Natarajan Muthusamy

  • Susheela Tridandapani

  • Michael Caliguiri

  • John C. Byrd

  • William E. Carson

Medical Centers

  • The Ohio State Univerisity, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Mammary carcinoma

  • Solid malignancies

Biomarkers

  • Bruton tyrosine kinase

  • Integrin alpha-4

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Stromal cell-derived factor 1

  • Cerebrospinal fluid

Drug/Treatment

  • Nitric oxide

  • Ibrutinib

  • L-Tyrosine

  • CXCL12

  • DMSO

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved